Correction: BMC Cardiovascular Disorders (2022) 22:360 https://doi.org/10.1186/s12872-022-02742-2

Following publication of the original article [1], the author has changed the table 3 and it should read as follows:

Characteristics during a follow-up period of 9 months in patients implanted with a CRT-D/P (mean ± SD) (n = 21)

  

Total

(n = 21)

Group 1

(n = 10)

Group 2

(n = 11)

P value

NYHA classification score

Before procedure

3.36 ± 0.50

3.4 ± 0.55

3.3 ± 0.52

0.840

3 Months after procedure

2.54 ± 0.52

2.6 ± 0.55

2.5 ± 0.55

0.770

9 Months after procedure

2.45 ± 0.52

2.4 ± 0.55

2.5 ± 0.55

0.770

P value

0.000

0.032

0.024

–

LVEDD (mm)

Before procedure

65.1 ± 9.1

68.2 ± 12.3

62.6 ± 5.3

0.336

3 Months after procedure

63.4 ± 10.1

64.4 ± 12.6

62.4 ± 8.3

0.781

9 Months after procedure

58.7 ± 10.2

62.2 ± 11.3

55.2 ± 8.7

0.303

P value

0.319

0.735

0.229

–

LVEF (%)

Before procedure

33.1 ± 3.0

32.0 ± 4.2

34.0 ± 1.3

0.302

3 Months after procedure

40.9 ± 7.0

41.6 ± 7.5

40.3 ± 7.3

0.782

9 Months after procedure

45.4 ± 8.7

45.0 ± 5.1

45.8 ± 12.0

0.894

P value

0.002

0.011

0.143

–

QRSd (ms)

Before procedure

168.2 ± 18.9

158.0 ± 13.0

176.7 ± 19.7

0.104

9 Months after procedure

131.4 ± 15.5

121.0 ± 3.8

133.3 ± 8.2

0.001

P value

0.001

0.005

0.011

–

NT-ProBNP (pg/ml)

Before procedure

2937 ± 1646

3240 ± 2258

2684 ± 1083

0.634

3 Months after procedure

1832 ± 1541

1151 ± 1774

2066 ± 1444

0.607

P value

0.014

0.04

0.219

–

VT/VF episodes (n)

8

3

5

0.175

Follow-up period (d)

574 ± 188

572 ± 207

575 ± 190

0.981

  1. LVEDD left ventricular end diastolic diameter, LVEF left ventricular ejection fraction, NT-proBNP N-terminal pro B type brain natriuretic peptide, NYHA New York Heart Association, QRSd QRS duration, VT ventricular tachycardia, VF ventricular fibrillation

Also, the baseline QRSd value were changed from 33.9 ± 3.9% to 33.1 ± 3.0%.

So, the text under "Baseline characteristics" will read as follows:

The echocardiographic indices, including LVEF, LVEDD, NYHA classification, and NT-proBNP are shown in Table 3. Baseline parameters were similar between the two groups (all P > 0.05). The baseline LVEF and the baseline QRSd (Fig. 2a) were 33.1 ± 3.0% and 168.2 ± 18.9 ms, respectively. At baseline, the QRSd of the two groups were matched (158.0 ± 13.0, vs. 176.7 ± 19.7, P > 0.05).

Also, text under "Follow‑up" will read as follow: Transthoracic echocardiogram (Fig. 3b) evaluation data at baseline and at the 3-month and 9-month follow- ups were available in all 21 patients receiving successful aCRT. As shown in Table 3, the symptoms and the median NYHA classification score improved significantly, with the latter decreasing from 3.36 ± 0.50 to 2.45 ± 0.52 (P = 0.016). LVEF (33.1 ± 3.0% vs. 45.4 ± 8.7%, P = 0.002) and NT-proBNP (2937 ± 1646 vs. 1832 ± 1541, P = 0.014) significantly improved at the follow-up visit. LVEDD (65.1 ± 9.1 mm vs. 58.7 ± 10.2 mm, P = 0.319) was improved at the 9-month follow-up visit, but the improvement was not significant.

The original article has been corrected.